1652 — Fusen Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$584.05m
- HK$848.02m
- CNY273.37m
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA
Brief: Fusen Pharmaceutical Says Agomelatine Tablets Approved For Marketing In China By NMPA
Brief: Fusen Pharmaceutical Says Dydrogesterone Tablet Receives Marketing Approval From PRC NMPA
Brief: Fusen Pharmaceutical Receives NMPA Approval To Market Glucosamine Sulfate Capsule In PRC
Brief: Fusen Pharmaceutical Obtains Approval For Marketing From NMPA As Phosphate Supplement
Brief: Fusen Pharmaceutical Announces Approval Issued By NMPA For Consistency Evaluation Of Nicardipine Hydrochloride Injection
Brief: Fusen Pharmaceutical Says Enzalutamide Soft Capsules Approved For Marketing by NMPA
Brief: Fusen Pharmaceutical's Unit Disposes Henan Fusen Intelligent Energy Conservation Technology Equity
Brief: Fusen Pharmaceutical Gets Approval For Metformin Empagliflozin Tablets
Brief: Fusen Pharmaceutical FY Loss Attributable RMB188.8 Million
Brief: Fusen Pharmaceutical Expects Loss Of RMB170 Million To RMB210 Million For FY
Brief: Fusen Pharmaceutical Says Acetylcysteine Effervescent Tablet Got Approval For Marketing
Brief: Fusen Pharmaceutical Says Application For Launching "Piracetam Injection" Accepted By NMPA
Brief: Fusen Pharmaceutical Says Cao Changcheng Chairman Of Board Passed Away
Brief: Fusen Pharmaceutical Says Eltrombopag Olamine Tablets Approved For Marketing By China NMPA
Brief: Fusen Pharmaceutical Says Application For Consistency Evaluation Of Nicardipine Hydrochloride Injection Accepted By NMPA